Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Acorda Therapeutics

Biogen Idec building

Biogen to open compassionate use programme for ALS patients with ‘rapidly progressive disease’

Move comes after mounting pressure from patients and campaigners

Biogen Idec building

Biogen reveals new data for MS therapies Tysabri and Vumerity

New data comes ahead of FDA decision on company's controversial Alzheimer’s drug aducanumab

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine is 100% effective in adolescents

Vaccine was found to be safe and effective in adolescents aged 12 to 15 years old

- PMLiVE

BioNTech forecasts €9.8bn in sales of Pfizer-partnered COVID-19 vaccine in 2021

Company also raised full year manufacturing capacity target for vaccine to 2.5 billion doses

- PMLiVE

Single Pfizer/BioNTech dose induces strong immune response to COVID-19

Study finds 99% of people generated a robust immune response against COVID-19 after single vaccine dose

- PMLiVE

Pfizer launches early study of COVID-19 antiviral therapeutic

Therapeutic candidate has demonstrated 'potent' in vivo activity against SARS-CoV-2

- PMLiVE

EU announces ‘top-up’ of ten million Pfizer/BioNTech vaccines in Q2

Brings total number of doses of the vaccine to be delivered in Q2 to over 200 million

- PMLiVE

Pfizer/BioNTech could supply three billion doses of COVID-19 vaccine in 2022

J&J reportedly facing vaccine supply issues in the EU

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine neutralises Brazil variant, suggests study

Neutralisation of variant 'roughly equivalent' to original SARS-CoV-2 strain

- PMLiVE

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

The European Medicines Agency is also reviewing an application for the drug

- PMLiVE

AbbVie buys exclusive right to acquire Mitokinin’s Parkinson’s asset

Company can acquire asset following the completion of IND enabling studies

- PMLiVE

UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people

Data suggests vaccine is 80% effective at preventing hospitalisations in over-80s

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links